Mayo Clinic Proceedings Home

Dual Chamber Pacing for Patients With Hypertrophic Obstructive Cardiomyopathy: A Clinical Perspective in 2000

      In some patients with hypertrophic cardiomyopathy, the dynamic left ventricular outflow tract obstructive gradient results in exercise-limiting symptoms of dyspnea, angina, and syncope. Dual chamber pacing has been proposed as a widely available alternative treatment for a subset of patients with symptomatic hypertrophic obstructive cardiomyopathy. Initial studies showed a reduction in gradient and an improvement in symptoms in almost 90% of patients with severe symptoms. We report the Mayo Clinic experience with dual chamber pacing in 38 patients with hypertrophic obstructive cardiomyopathy who had permanent pacemakers implanted for limiting symptoms intractable to medical therapy. After a mean ± SD follow-up of 24±14 months, subjective improvement was reported in 47% of patients. However, there was no statistical difference between the maximal oxygen consumption at last follow-up and AAI pacing (atrial sensing and atrial pacing) (18.6±1.1 mL·kg−1.min−1) (ie, when the pacemaker was implanted but not pacing continuously). This article discusses the clinical perspective on the utility of dual chamber pacing for patients with hypertrophic obstructive cardiomyopathy.
      MVo2 (maximal oxygen consumption)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wiglc HD
        • Rakowski H
        • Kimball BP
        • Williams WG
        Hypertrophie cardiomyopathy: clinical spectrum and treatment.
        Circulation. 1995; 92: 1680-1692
        • Louie KE
        • Edwards III, LC
        Hypertrophie cardiomyopathy.
        Prog Cardiovasc Dis. 1994; 36: 275-308
        • Maron BJ
        Hypertrophie cardiomyopathy.
        Carr Probl Cardiol. 1993; 18: 639-704
        • Maran BJ
        • Bonow RO
        • Cannon III, RO
        • Leon MB
        • Epstein SE
        Hypertrophie cardiomyopathy: interrelations of clinical manifestations, pathophvsiology, and therapy (firsl of two parts).
        N Engt J Med. 1987; 316: 780-789
        • Marian AJ
        • Roberts R
        Recent advances in the molecular genetics of hypertrophie cardiomyopathy.
        Circulation. 1995; 92: 1336-1347
        • McCully RB
        • Nishimura RA
        • Tajik AJ
        • Schaff HV
        • Danielson GK
        Extent of clinical improvement after surgical treatment of hypertrophie obstructive cardiomyopathy.
        Circulation. 1996; 94: 467-471
        • ten Berg JM
        • Suttorp MJ
        • Knaepen PJ
        • Emst SM
        • Vermeulen FE
        • Jaarsma W
        Hypertrophie obstructive cardiomyopathy: initial results and long-term follow-up after Morrow septal myectomy.
        Circulation. 1994; 90: 1781-1785
        • Cannon III, RO
        • Dilsizian V
        • O'Gara PT
        • et al.
        Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophie cardiomyopathy.
        Circulation. 1992; 85: 1039-1045
        • Cohn LH
        • Trehan H
        • Collins Jr, JJ
        Long-term follow-up of patients undergoing myolomy/myectomy for obstructive hypertrophie cardiomyopathy.
        Am J Cardiol. 1992; 70: 657-660
        • Fananapazir L
        • Epstein ND
        • Curiel RV
        • Panza JA
        • Tripodi D
        • McAreavey D
        Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophie cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
        Circulation. 1994; 90: 273I-2742
        • Fananapazir L
        • Cannon III, RO
        • Tripodi D
        • Panza JA
        Impact of dual-chamber permanent pacing in patients with obstructive hyper-trophic cardiomyopathy with symptoms refractory to verapamil and bela-adrenergic btockcr therapy.
        Circulation. 1992; 85: 2I49-2161
        • Jeanrenaud X
        • Goy JJ
        • Kappenberger L
        Effects of dual-chamber pacing in hypertrophie obstructive cardiomyopathy.
        Lancet. 1992; 339: 1318-1323
        • Braunwald E
        Induced septal infarction: a new therapeutic strategy for hypertrophie obstructive cardiomyopathy [editorial].
        Circulation. 1997; 95: 1981-1982
        • Oakley CM
        Non-surgical ablation of the ventricular septum for the treatment of hypertrophie cardiomyopathy [editorial].
        Br Heart J. 1995; 74: 479-480
        • Spirito P
        • McKenna WJ
        • Schulthciss HP
        DDD pacing in obstructive HCM [letter].
        Circulation. 1995; 92: 1670-1673
        • Nishimura RA
        • Danielson GK
        Dual chamber pacing for hyper-trophic obstructive cardiomyopathy: has its lime come? [editoriaij.
        Br Heart J. 1993; 70: 301-303
        • Kappenberger L
        • Linde C
        • Dauben C
        • et al.
        PIC Study Group. Pacing in hypertrophie obstructive cardiomyopathy: a randomized crossover study.
        Eur Heart J. 1997; 18: 1249-1256
        • Linde C
        • Gadler F
        • Kappenberger L
        • Ryden L
        • P1C Study Group
        Pacing In Cardiomyopathy. Placebo effect of pacemaker implantation in obstructive hypertrophie cardiomyopathy.
        Am J Cardiol. 1999; 83: 903-907
        • Nishimura RA
        • Trusty JM
        • Hayes DL
        • et al.
        Dual-chamber pacing for hypertrophie cardiomyopathy: a randomized, double-blind, crossover trial.
        J Am Coll Cardiol. 1997; 29: 435-441
        • Slade AK
        • Sadoul N
        • Shapiro L
        • et al.
        DDD pacing in hypertrophie cardiomyopathy: a multicentre clinical experience.
        Heart. 1996; 75: 44-49
        • Maron BJ
        • Nishimura RA
        • McKenna WJ
        • Rakowski H
        • Joscphson ME
        • Kieval RS
        Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophie cardiomyopathy: a randomized, double-blind, crossover study (M-PATHY).
        Circulation. 1999; 99: 2927-2933
        • Hassenstein P
        • Storch HH
        • Schmitz W
        Erfahrungen mit der Schrittmacherdauerbehandlung bei Patienten mit obstruktiver KaTdiomyopathie.
        Thoraxchir Vask Chir. 1975; 23: 496-498
        • Hassenstein P
        • Wolter HH
        Therapeutischer Beherrschung einer bedrohlichen Situation bei der idiopathisehen hypertrophischen Subaortenstenose.
        Verh Dtsch Ges Kreislaufforsch. 1967; 33: 242-246
        • Duck HJ
        • Hutschenreiter W
        • Pankau H
        • Trcnckmann H
        Vorhof-synchrone Vcntrikelstimulation mit verkürzter a.v. Verzogerungs-zeit als Therapieprinzip der hypertrophischen obstruktiven Kardio-myopathie.
        Z Gesamte Inn Med. 1984; 39: 437-447
        • Spirito P
        • Bellonc P
        Natural history of hypertrophie cardiomyopathy.
        Br Heart J. 1994; 72: S10-S12
        • Wigle ED
        Impaired left ventricular relaxation in hypertrophie cardiomyopathy: relation to extent of hypertrophy.
        J Am Coll Cardiol. 1990; 15: 814-815
        • Wigle ED
        • Sasson Z
        • Henderson MA
        • et al.
        Hypertrophie cardiomyopathy: the importance of the site and the extent of hypertrophy: a review.
        Prog Cardiovasc Dis. 1985; 28: 1-83
        • Pak PH
        • Maughan WL
        • Baughman KL
        • Kieval RS
        • Kass DA
        Mechanism of acute mechanical benefit from VDD pacing in hy-pcrlrophied heart: similarity of responses in hypertrophie cardiomyopathy and hypertensive heart disease.
        Circulation. 1998; 98: 242-248
        • Nishimura RA
        • Hayes DL
        • Llstrup DM
        • Holmes Jr, DR
        • Tajik AJ
        Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophie cardiomyopathy: acute Dopplcr echocardiographic and catheterization hemodynamic study.
        J Am Coll Cardiol. 1996; 27: 421-430
        • Symanski JD
        • Nishimura RA
        The use of pacemakers in the treatment of cardiomyopathies.
        Curr Probl Cardiol. 1996; 21: 385-443
        • Gadler F
        • Linde C
        • Juhlin-Dannfeldt A
        • Ribeiro A
        • Ryden L
        Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophie obstructive cardiomyopathy.
        J Am Coll Cardiol. 1996; 27: 1219-1224
        • Ommen SR
        • Nishimura RA
        • Squires RW
        • Schaff HV
        • Danielson GK
        • Tajik AJ
        Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophie obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points.
        J Am Coll Cardiol. 1999; 34: 191-196
        • Knight C
        • Kurbaan AS
        • Seggewiss H
        • et al.
        Nonsurgical septal reduction for hypertrophie obstructive cardiomyopathy: outcome in the first series of patients.
        Circulation. 1997; 95: 2075-2081
        • Sigwart U
        Non-surgical myocardial reduction for hypertrophie obstructive cardiomyopathy.
        Lancet. 1995; 346: 211-214